Antonio
Gómez Caamaño
Hospital Vall d'Hebron
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (13)
2023
-
Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types
JNCI Cancer Spectrum, Vol. 7, Núm. 6
2022
-
Effect of LHRH analogs on lower urinary tract symptoms associated with advanced prostate cancer in real clinical practice: ANALUTS study
Neurourology and Urodynamics, Vol. 41, Núm. 8, pp. 1824-1833
-
Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort
eBioMedicine, Vol. 84
-
Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer
Radiotherapy and Oncology, Vol. 168, pp. 75-82
2021
-
Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain
Health and Quality of Life Outcomes, Vol. 19, Núm. 1
2019
-
REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer
Radiotherapy and Oncology, Vol. 138, pp. 59-67
2016
-
Corrigendum to "Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance". [Rep. Pract. Oncol. Radiother. 20 (2015) 259-272]
Reports of Practical Oncology and Radiotherapy
-
GRAY-B: An open label multicenter phase-2 GEM study on ipilimumab and radiation in patients with melanoma and brain metastases
Annals of Oncology, Vol. 27, pp. vi383
-
Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients
Radiotherapy and Oncology, Vol. 121, Núm. 3, pp. 431-439
-
Management of prostate cancer patients following radiation therapy after radical surgery referred from urology to radiation oncology departments in Spain
Clinical and Translational Oncology, Vol. 18, Núm. 9, pp. 884-892
2015
-
Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance
Reports of Practical Oncology and Radiotherapy, Vol. 20, Núm. 4, pp. 259-272
2014
-
Infrastructures, treatment modalities, and workload of radiation oncology departments in Spain with special attention to prostate cancer
Clinical and Translational Oncology, Vol. 16, Núm. 5, pp. 447-454
2013
-
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572